Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

NICE set to hand Bayer wider recommendation for Xarelto

Backs drug’s use to treat pulmonary embolism and prevent DVT

- PMLiVE

Charting a sea change in medical education

The medical education landscape has changed significantly over recent years. There are many reasons for this sea change, but two stand out...

- PMLiVE

FDA approves Alcon eye drug Simbrinza

Fixed-combination licensed to treat glaucoma patients in the US

- PMLiVE

Team Gold

Putting a best practice sharing model in place

- PMLiVE

Online social gaming campaign takes aim at cancer

EPAAC's I'm a Fan of Life initiative focuses on cancer prevention

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

Lundbeck launches alcohol drug Selincro in Europe

Norway, Finland, Poland and the Baltic countries chosen as first markets

- PMLiVE

European drug applications ‘stable but more complex in 2012’

Despite austerity measures, EMA's annual report shows signs of biopharma resilience

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

Ipsos promotes Jackie Ilacqua to global head of syndicated services

Will retain role as president of global oncology

- PMLiVE

Adapt and overcome: Adaptive trial design in research

The pharma industry is slowly starting to embrace adaptive trial design, though not as quickly as once hoped, thanks largely to regulatory uncertainty

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links